Ocular Therapeutix rises on plans to fast-track FDA filing for eye disease drug

Shares of Ocular Therapeutix OCUL.O rise 13.5% to $14.28 in premarket trading

OCUL says its plans to submit a marketing application for its experimental eye disease drug, Axpaxli, to treat wet age-related macular degeneration after one-year data from its ongoing late-stage trial, expected in the first quarter of 2026

Wet AMD is a leading cause of vision loss in older adults, marked by abnormal blood vessel growth in the retina

Company says the study is designed to show superiority over Regeneron Pharma's REGN.O Eylea and aligns with recent FDA guidance that a single, well-controlled trial may support approval

As of last close, stock up 47.3% YTD